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Proardrythmla is an evolving concept in cardiology and has
been variously defined (I). In general, the term proanlsyth-
mia is applied when then is appearance
of a new arrhythmia
or worsening of arrhythmia after antiarrhythmlc drug treat-
ment is started In comparison with drug-free conditions .
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desariptive and provides iotormadm such as incidence with
a particular drug or series of drug (I-A and is seldom
placebo controlled. It Is often implied or inferred tints there
is a cease-effect relation between the use of an andarrhyth.
role drug and worsening of the arrhythmia under seek
dnumstaecs. Whereas most cardiolcgists accept the con-
cept that an altiarrhythnnic drug can cause worsening of
arrhythmia, causality is most clearly established in the
clinical paradigm of class IA antiarrhythde drug and
torndedopoimesventdculrtachycadia(Sy)
.Otherthings
can mimic worsening of arrhythmia caused by antiarhyth.
mic drug therapy. New or increased
arrhythmia
may a.moly
represent spontaneous variability of arrhythmia and ieeM-
cacy d the drug rather than proarhythmia. Furthermoe,
the clinical significance of increased frequency of nonfatal
arrhythmia when aetiarhylhmb drug therapy is started
remains unknown (10). Accordingly, the present analysis
was undertaken using the data bases from the Cardiac
or3t-roewvw m
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Arrhythmia Suppression Trial (CAST and CAST-11) and its
piel study, the Cardiac Arrhythmia Pike Study (CAPS) . The
objectives were to determine the incidence, patient charac-
teristics and clinical significance of worsening ventricular
arrhythimia during drug titration with the anliarrhythmic
drugs used in these studies of postmyocardial infarction
patients with frequent (?6!h) ventricular premature depolar-
izalions and to assess the likelihood that these drugs caused
the worsening of arrhythmia .
Methods
CAST and CAPS protocols. Descriptions of the CAST
(Iq, CAST-11 (12) and CAPS (131 protocols have been
previously published . Briefly, CAST and CAST-11 were
double-blind, placebo-controlled randomized trials designed
to test the hypothesis that suppression of ventricular prema-
ture depolarization that cause mild or no symptoms would
reduce the incidence of arrhythmic death in patients with
prior myocardial infraction. They were preceded by the pilot
study. CAPS, which was also a double-blind . placebo-
Controlled randomized study that evaluated a number of
antiatrhythmic drugs being considered for inclusion in CAST
and CAST-11 in patients with a recent myocardial infarction .
There were some minor differences in patients and protocols
of the three phases of the study and these have been outlined
in a previous publication (14). The important differences
with respect to the present study are highlighted here .
The protocols and consent forms were reviewed and
approved by the Institutional Review Boards of each of the
participating centers . and each institutional Review Board
met U.S. Health and Human Services guidelines . In CAPS .
patients were immediately randomized to double-blind ther-
apy with one offeuractive drugs ore parallel placebo . CAPS
patients were in hospital for at tenet 4 h after the start of
drag therapy, and most had continuous electrocardiographic
(ECG) monitoring. However, 24-h ambulatory ECO record-
ings for determination of suppression of ventricular prema-
ture depolarization were not done until 5 to ID days after
initiation of drug therapy. A few patients did not have 24h
ECG recordings because they were intolerant tithe drugs m
withdrew.
In CAST. initiation of treatment was unblnded and not
pleeebo controlled. When left ventricular ejection fraction
was <0 .30
. flecaimide was not used
. During the open-label
titration phase of CAST, which was an outpatient study,
ambulatory EM
recordings
were done only in patients who
tolerated a particular drug or dosage . These recordings were
done at least 3 days after titration was started . Early
recordings were not done in patients who were intolerant of
the drop because of adverse clinical symptoms, or in these
who withdrew.
During the first 2 weeks of therapy (acute study) in
CAST-lit. patients were randomized to treatment with the
lowest dose of mmicizi ne (600 mg/day) or placebo . Ambu-
latory ECO
recordings
were obtained at the end of the acute
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study in all patients who were on active drug and who were
tolemnl of this first dose
. The only drug anal in CAST-Ii was
moricizine. After the acute study, CAST-11 patients whose
ventricular premature depolarization were not suppressed
or who were receiving placebo entered an open-label drug
titration phase. The criteria for doing a 24-h a
mb dstory
ECG recording during the open-lapel titration phase of
CAST-11 were the same as those used in VAST. Patients
who were on placebo for the acute study were not electro-
cardiogaphically monitored while on placebo and those who
were intolerant of active drug or withdrew were not etearo-
cardiographically monitored .
In all three studies, attempts to suppress ventricular
premature depolarization were continued until specified
criteria were achieved (14) without intolerable adverse
effects or until 90 days had elapsed
. The duration during
which patients were included in the present analysis to
monitor for occurrence of early proarrhythmia consisted of
the time spent in titration . Assessment for occurrence of
early proarrhythmia ended when patients either left the
titration phase am! entered the long-tent phase or left the
titration phase but did not enter the long-term phase for
whatever reason, including exceeding 90 days from qualifi-
cation . The average duration of exposure of the 3,840
patients for occurrence of early proarrhythmia was 23 ± 19
days (mean s SD). Before December 1989, partial suppres-
sion (gust is . insufficient decrease in ventricular premature
depolarization) was recorded only for the final drt*dm
evaluated. Similarly, increased ventricular premature depo-
larizations that did not meet the CAPS definition
of-
pram-rhythmic"
was not noted in the data base before that date .
Patients with partial setpprersian on earlier drugs4lnages,
patients with increased ventricular premature depolariza-
tion not meeting the CAPS detention of "proarrhythmia"
and intolerant patients cannot be distinguished from one
another in all instances and are grouped together as "not
suppressed."
In CAPS patients were assigned to the drug that was more
efficacious or better toletmed, or both, and followed for I
year after randomization. One group continued to take
placebo . In the long-term phases of CAST and CAST-11,
patients with full or partial suppression and no intolerable
adverse effects after initial treatment were re-randomized to
the most effective drug and dose, or a matching placebo .
Patients with increased frequency of verur(cula premature
depolarizations arintoerance on all drugs were not random-
ized in the long-term phase of CAST and CAST-11. All
CAST patients on encainide, Ilecainide or their placebos
(1,593 patients) and those who entered titration but were not
randomized (408 patients) were followed up until death
.
cardiac arrest, withdrawal or April 19
. 1989 (average expo-
sure 278 days)
. The CAST patients randomized to moricizine
or placebo in the long-tam phase (369 patients) continued
their therapy and are considered to be CAST-II patients for
purposes of analysis of average exposure time . The CAST-11
patients were followed up until death, cardiac arrest, with-
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drawal or July 31, 1991 (1,158 randomized and 380 sonraw
domized patients; average exposure 447 days) .
Dan analysis. Averaged data are presented
as mean ± I
SD. Comparison of patient characteristics or proportions are
by the chi-square or t statistic, as appropriate . Multiveriable
analysis for predictors of mortality used the Cox proper,
tional hazards regression model (I5) . The time to a specific
adverse event was analyzed by the method of Kaplan and
Meier (16).
DefiNlons. Arrhythmic death or resuscitated cardiac
arrest. These events included witnessed instantaneous
death in the absence of severe left ventricular failure or
shock that in itself may have been expected to cause death ;
resuscitated ventricular fibrillation (or If no rhythm docu-
mentation was available, resuscitated cardiac arrest ; that is,
documented and nonfatal ventricular tachyeardia was are
counted as an "arrhythmic death"), or unwitoessed death
without other known nonce iliac causes .
Total mortality or resuscitated cardiac arrest . These
events included all deaths, cardiac and noncardiec . and
resuscitated cardiac arrest .
Susralned ventricular tachycardla . Ventricular tachycer
din was defined as ta3 successive complexes at 2120 beats!
ndn ; sustained ventricular tachycardia was defined as that
lasting z30 s or requiring termination because of hemody-
namic collapse
.
Increased ventricular premature depalarizatlons. It Is
customary to minimize inclusion of increased vemrinwlar
premature depolarization and rams of unsustained ventric-
ular tachycardia due to spontaneous variability by requiring
a marked increase in ventricular premature depolarizatioua
and unsustained ventricular tachycardia frequency. In the
present analysis, the CAPS definition (13) of increased
ventricular premature depolarizations and runs of unaus-
tained ventricular tachycardia was used, The CAPS defini .
tion was established on the basis of the work of others
(17,18), which showed
an approximately constant variance
for the natural logarithm of hourly frequency of ventricular
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Pigme 1. Allocation of study patients . CAPS -
Cardiac Anhyth®a Pllot Study; CAST
-
Cardiac
Arrhythmic Suppression Trial; ECO - elechecar-
diagam; VPD
-
ventricular premature depolariza-
tion.
premature depolarimdons. The CAPS Investigators esti-
mated that a IOfold increase at 10 and a 2-fold increase at
1,500 ventricular premature depohlrlzationsb was approxi-
mately correct. The CAPS definition for increased ventricu-
lar premature depolarization is as follows:
On y) 2 3
.118 +
0.646 On x), where x = ventricular premature depolarize
dons per hour at baseline and y - ventricular premature
depolarrsat ons per hour dining drug
therapy;
or 250 rams of
unsuatained ventricular tnebycnrdia per 24 h when there
were <5 runs at baseline or a 210-fold increase in suns of
unsustained ventricular tacleycmdia when there were 25
runs per 24 h at baseline. When either or both of these
aiterla for worsening arrhythmia was or were met, they
were termed increased ventricular premature depolarize-
dons. When these definitions were met in CAPS Indents .
antrrhythmle drug therapy was discontinued and the 24-h
ambulatory HCG rncerdi - was repented after drug washout
for at least S drug half-lives . Increased ventricular prematura
depolarization was considered to be confirmed if the fre-
quency of arrhythmia on the treatment ambulatory ECO
recording met the deflaiibn cited previously on the basis of
the frequency of ventricular premature depolarization m
the washout tape. Antiurhythmic drug washout was not
routinely used as an attempt to confirm increased ventricular
premature depolarization in the CAST and CAST-11 pa-
tients .
Results
Patients. The allocation of study patients is presented in
Figure 1. The total number of patients available for analysis
of early arrhythmic death and sustained but nonfatal vestric
ular techycmdia was 3,840 and for analysis of early in-
creased ventricular premature depokuizations the number
was 3,543 . A selection of baseline characteristics of the bitter
patients, grouped according to entry phase, is presented in
Table 1 . In general, patients entered during the later phases
of the study had more advanced hear disease . They were
CAPS CAST CASTII
M Le-11
Tnabnp4
W
E_.s
31,a~f1
Ne IHe, eW 7I _Ian 1 `1m
M W55
saw eon
24-H, EM \~
Rise
\
n
\o
Maids; only
a4H EGG
2W A.0. \o \R18 \s
Cnq
only
24NaEDG
latAmwa se
1042 am
sag
8F
.
II
Y
s
e
	
:
:
5
°
e
-
	
a
	
°s
d
e
a
~
s
d
d
e
V
	
V
	
V
 
V
	
V
 
V
	
V
	
V
	
V
 
V
v
V
 
V
 
V
 
V
 
V
M
a
p
ea
	
_
	
C
9
X
,
	
;
j
m
9
2
r
e
y
 
M
E
m
9
.
~
 
0
x
~
~
g
I
V
 
W a
a
a
l
m
l
I
M
I
N
7
~
u
~
7
t
.
8
	
a
*
6
	
-
r
s
2
9
u
	
3
	
~
	
5
b
~
	
3
3
	
W
3
n
A
n
E
:
-
3
 
2
E
	
'f
i
g
H
	
L
L
A
	
J
A
	
7
1
. 0
c
~
c
3
c
T
c
7
c
~
~
	
~
S
U
o
.
n
 
8
.
5
 
T
a
'
3
9
'
a
d
•
~
~
E
e
$
	
V
•
S
S
~
e
S
S
~
.
.
•
~
'
.
.
.
E
~
4
.
9
8
O
V
 
e
~
'
v
s5
•
	
~
d
d
d
y
l
	
N
	
V
I
 
N
	
N
	
N
r
t
	
M
.
I
~
H
 
4
1
 
1
1
H
A
n
V
I
V
I
	
R
=
-
F
_
a
t
=
T
,
i
S
~
I
K
'
R
 
m
m
4
1
'
F
'
~
 
o
 
^
a
•
	
s
.
.
_
_
~
a
•
~
	
w
a
z
a
s
~
~
a
d
^
-
-
=
~
w
a
•
~
~
~
a
s
~
:
e
s
H
	
V
 
N
	
N
•
	
7
E
:
.
C z
1
9
S
M
]ACC
Vol. 23, No. S
April 199r<113D-40
ao
1-
J
F
O
2
20
V
a
- Increased VPDs
- No Increased YPDs, Not Suppressed
- No Increased YPD,, Suppressed
Log Rank p'00.0001
12
MONTHS
24
Figure 3. Reldion between early increased ventricular promoters
depdariratioae (VPDs) and long-term
a0-auto
mouality for the
patient groups presented in Table 4 (see text),
A feather confounder of the long-term mortality analysis
was that the CAPS patients were only followed up for I year
from randomization. Accordingly, they were excluded from
this analysis and the data presented are confined to that
provided by the CAST and CAST-11 patients .
A Kaplaa-Meier analysis was done competing the pa-
tients with increased ventricular premature dcpolarizations
and those without increased ventricular premature depolar
izations (not shown). The occurrence of early increased
ventricular premature depolarization was associated with
increased overran mortality (p = ( .0012) and was even more
straggly associated with increased risk of arrhythmic death
(p < 0
.001).
A KaplrMeier analysis was alto done comparing the
patents with Increased ventricular premature depolariza-
oads and the two subgroups (suppressed and "not sup .
pressed") of those without increased ventricular premature
depolarizadwis. and the results arc fusunted in Figures 3
and 4 . With regard to the end point of total morte4y (Fig . 3),
the patients with increased ventricular premature depoler .
landaus had the greatest event rate, and the patients without
increased ventricular premature depdarizations and whose
vemrkWu pretgetme depolarizarions were suppressed an
the first active drug had the lowest event rote. Patients
without increased ventricular premnne thpoladzadous
who were "no suppressed" bad as intermediate event rate .
Whit rnmd m the tad point of erhythmic death (Fig. 4),
patients with increased ventricular premature depolarriza
lines again had the greatest argued ram but in this instance
whether ventricular premature depolstirations were sup.
pressed on the first active drug or the patient was "am
suppressed" did no segregate the two subgroups of those
without increased ventricular premature deplarizations .
The Coa regression model resuhsdemonstrated that arty
increased ventricular pimwure depolmizadoos was an in-
dependent predictor of mortaliy, particularly arrhythmic
dath. All variables that were univanately related to mormF
ity with a p < 0.1 were included in the model . Twenty-eight
such variables were identified for the end point of total
verse ET AL.
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ec r
I.
4
so
0
g
w
20
U
IUL
Inaaned YPDO
No
Increased VPD1, Not Suppressed
No Inoressad VPD,.
Rwpressed
Lug 9eok p'00.0001
r
12
	
24
MONTHS
1137
Finum 4 .
ltelnIiop between early increased ventricular premature
dcpe(aeizativm (Viva) and lone tern arrhythmic mortality for the
patient groups pigmented in Table 4 (set tern .
mortality and 2b were identified for the end point of arrhyth-
mic death. The relative risk associated with early increased
ventricular premature depolarization, fur the end point of
all-cause death or resuscitated cardiac arrest was 1 .59 with a
p value of 0.046 . For the end point of arrhythmic death or
resuscitated cardiac arrest, the relative risk was 2 .34 with a
p value of 0.0053.
Discussion
Patients. Although the patient characteristics of those
who entered at various stages of
the study are generally
similar
. there arc some differences and caution is
necessary
in comparison across the three plusses of the study . The
group under study is predominantly composed of males with
recent ayocardial irdrction, frequent ventricular premature
depola iations (2!!Ih) and compromised left ventricular
function . In this regard, the patient group is more homoge
occus than those usually reported in studies of the incidence
of proenhythmis (1-7, l0). Nevertheless, the findings of this
study may not he genemlizsde to those with structurally
normal beans . other forms of hart disease or even those
with o•sonary heart disease of differing severity
. Impor-
tandy, with respect to previous studies on "proarhythmia'
defined by increased frequency of ventricular premature
deplarizations and runs of unsuslained ventricular tachy-
eardia, it must he stressed that the present study included
patients with xh ventricular premature deplariratiou/h,
whereas others reported on patients with a30 ventricular
premature deplarlzadonath (2) . This aspect of the present
study is discussed further in the following section .
Early sustained venricular rmiycardfa . There was no
increased risk of sustained but nonfatal ventricular tachycar-
dia occurring during drug titration, despite the Increased risk
of
arrhythmic
death during initiation of therapy with these
drugs . This finding is consistent with other lines of evidence
that also suggest a dissociation between drug suppression of
arrhythmias by am antiarrhythreic drug and mortality . In the
long-term phases of CAST after ventricular premature de-
1138
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polarization suppression was documented, there were an
difaences in the Wue-term incidences of nonfatal ventricu-
lar taehycardia between those on placebo and those on
active dug
(11). However, arhydhmic death was increased
significantly in patients taking encalnide and fieealnide (11)
and leaded to be increased in those taking morieszine (12).
Furthermore, a u ela-analysis of lidoumina use in acute
myocardial infarction has shown that the drug reduces the
incidence of ventricular fibrillatons but increases mortality
(19). Similar analyses with respect to quinidine in atria)
fiballalw (2h) and ventricular arrhylhmias (21) have sug-
geaed that this drug can also increase mortality ie patients
whose arrhythmia is suppressed. It is quite likely, however .
that the drugs increased the incidence of final arshythmlsa
(see next section) .
Early arrhyrhmrr death . The effects of Ihese drugs on
ardlythmic death during the long-term phase of the study are
well known and have been reliably estimated because the
study design included placebo control (11,12) . The effect of
the digs on arrhythmic death during initation of therapy
and drug titration is more difficult to measure accurately
because of a lack of appropriate control groups for all
patients . However, in the comparisons that can be made, to
prom analysis indicates that these class I antinwhythmic
drugs cause a threefold increase in arrhythmic death (0.5%
vs. 1
.6%) during initiation of therapy in Ibis group of
patients
. This relative risk is comparable with the three-fold
increase in arrhythmic death caused by eweainide
and
fieainide during the long-term phase of CAST (11). The
overall risk (1 .6%), however, is considerably lower than do
observed with patients who have already had an episode of
sustained ventricular tachycardia or fibrillation and are then
started on a class I mdimrhylhmic drug (4,7) .
Early lecreased ventricalor prrmalure depolarizarLwru .
The incidence of "proanhsythmia" during drug dusting
determined by Increased frequency ni'vemricular premature
depolarization or runs d nowustalned venticular tachy-
cardia was quite low and most notably was indistinguishable
front [hat seen during phtabo tmalment in the CAPS phase
of the study . The incidence of "proarrhythmia" has been
reported to be higher in the case or encainide (5). but the
lstterpaiicm group was much smaler(oay 25 patients) . less
homogeneous and the definition
of "proarrhythmia" was
somewhat different in that report . Similarly, the iacluence of
"aggravation of arrhythmla" hat been reported to be higher
with these drugs but again smaller groups were studied and
the definition used for "aggavaion of arrhylhnda" is diffier-
:.al from that of the present study (3) . In spite of such
inter-study differences, the incidence or"proarrhylhmi" us
defiled try increased frequency of ventricular premature
depolarlutlons and runs of ncrunstained ventricular tachy-
ardia found for the drugs used in the present study is similar
to that reported in several previous smaller studies with
more variable patient groups (2,5,6) . None of The studies
cited included placebo control .
As has been noted, the incidence of increased ventricular
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premature depolatvatious was no greater an the first active
drug than it was on placebo in CAPS . It must be emphasized .
however, that the definition of such "proarrhythntia" is
based u previous studies (17) with less homogeneous
groups of patients who had m re frequent ventricular pre-
mature depolmixaions. The vulnerability of this definition of
"proarrhytkom" when the frequency of ventricular prema-
ture depolarizatiasa is low matd the variance is not constant
has been well recognized (3,22)
.
Relerion to venhiculwfracrion . It is or interest to note
that although reduced ventricular function is strongly asso-
ciated with increased arrhythmic death i the CAST popu-
lations (11 .23) and with peuurhythmic sustained ventricular
tachyenNia and arritythnde death
(4
.7), the occurrence of
early increased ventrierlar premature depolarization during
drug titration i the present study was unrelated or only
weakly related to reduced left ventricular ejection fraction .
Provloua data in ambler study stoups suggest an association
between Increased ventricular premature depalarlzafions
and presence
of structural heart dlsense (2) or reduced
ventricular function (3).
and it has been frequently stated
that all "pmnrebythmic" responses are related to reduced
left ventricular function (1,23) . The weak association be-
tween increased venricuar premature depolarbadmes ad
poor ventricular function in the present study may be
became many who had a mmked increase in ventricular
premature depalmizations did not tangy have "proaerhyrh-
I,& ,
.
Baseline
chararrrrin*s ofpasiee u with Increased ven-
tricelar premawre depolarrrasins
. Patients who bad eaAy
increased venhicahtr pr~wure depolarizatotts during drug
titration dibred from these who did not in some baseline
characteristics
. There was a higheriocidenee of nmn-Q wave
myocardial lefarctlon in the group who had increased ven-
tticulsi prmaure depdrlzatons . A potential association
between iachclrdc episodes and futnl arrhythmia in CAST
has ban suggested (11
.24)
.
NW-Q wave myocardial hnfrc-
tin Is associated with more frequent episodes of poslinfuse
don myocmdil isshemi (25). The assndstln d increased
ventricular premature depolarieations and Pop--Q wave myo-
cardial
infarction suggests that episodic iachemia may lead to
increased frequency of vanhieuler premature depolrira-
tioos, which in turn may bee marker for arrhythmic death .
Palmas who had Increased vermicular premature depolas
izatow were also move frequently taking digitalis and had
higher rest hear) rates. The meaning of these findings is
unclear, but there are known complex interrelations between
heart rest . left ventricular function and frequency of ventric-
ular premature depolarleatkos (26). Fruthermore, it is well
recognized that digitalis can lead to an increased frequency
of ventricular premature depolaizalions . The data of the
present study suggest that a large portion of what has been
termed "pmarrhylhmia" is spontaneous variability in at.
rhythmic frequency and luck of efficacy of drug therapy
rather than being specifically druginducd . The observation
that the basegoe frequency of ventricular premature depo-
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huizations was significantly lower in the patients that had
increased ventricular premature depolarizations is at least
circumstantial
evidence that the mathematical definition of
increased ventricular premature depolarization used may
be insuffielently rigorous when the frequency of ventricular
premature depolarizations Is low . This particular definition
of "promrhythmia" tended to select patients who had a
lower frequency of ventricular premature depolarization on
their baseline ambulatory ECG recording
.
,lee
rsf
drag washout an increased venrrfcalar prema-
lure depdlariretians. The CAPS data an the small number
of patients who had a washout ambulatory ECG recording
support the concept that many of the episodes of such
"preatrhythnda" were nor drub induced. Specifically, of
those meeting this definition of "praartfiythmia," more than
half the episodes could not be confirmed by washout,
whether the treatment was active drug or placebo.
Relation between early increased vearrfralar
premature
depola4zarlont on first
and
second drag. The data compar-
ing the Incidence of increased ventricular premature depo-
huizations during titration with the first drug with that during
titration ofa second drug suggests that it was a characteristic
intrinsic to a particular patient
. It must be remembered that
this analysis only includes patients who were not suppressed
on the first drug
or who were intolerant of it . and a repeat
drug-free ambulatory ECG was not done between the two
drug trials. A small number of these patients did have a
second drug-free ambulatory ECG done during drug tltra-
tan. The latter data are too fagmentary to be helpful . They
suggest at least sane of the positive concordance arc a
recurrence of Increased ventricular premature depolariza .
dons, but most are persistence of baseline variation
. It has
been stated that there is no relation between increased
ventricular ptemasure depolmizations on one drug and its
occurrence on another drug
(3) .
although such a relation has
been noted in the
case of more serious proarrhythmia (4).
The present data suggest there Is such a relation but do not
ncematefy delineate how much is recurrence
and
how much
is persistence
o baseline variation.
Long
term clinical silraWwece of increased ventrerulnr
premature deiroh rizations . The present report is she First to
note that increased ventricular premature depolarization
during titration with an amimrhythmic drug predicts a higher
likelihood
of
arrhythmic death, even though treatment with
the drug is not contitnred
. Until now, the significance of
increased ventricular premature depolarization has been
said to be uncertain or questionable (1 .10.23). This observa-
tion is not diminished in clinical Importance by the possibil-
ity that in some cases the increase in arrhythmia may not
have been caused by the drugs . h is interesting to note that
patients whose ventricular premature depolarizations were
suppressed on the fast drug tested had improved survival,
even though the antiarrhythmic drug was not continued . One
can speculate that ease of snppreseibiliry and markedly
increased
ventricular
premature depolarization frequency on
the first drug are the opposite poles of the same phenome-
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non- However, it is it[teresting to note that ease of suppress-
ibility was found to be related m total mortality (Fig
. 3),
whereas increased ventricular premature depolarization is
specifically related to arrhythmic mortality (Fig . 4 and Cox
regression results). It is important to state that the observa-
tion of long-term poor outcome in relation to increased
ventricular premature depolarization during drug titration
may net be generalizable to other patient groups,
portico-
lady
to those that have structurally normal hearts . Whether
increased venricular premature depolar izations during and-
arrhythmic drug titration is causally related to the observed
increase in arrhythmic mortality or merely an associated
phenomenon is purely speculative . One possible explanation
is that patients with greater random variability in ventricular
premature depolarization frequency have unstable and
changing clectrophysioloe(c substra es that predispose them
not only to variability in ventricular pr
.matme depolariza-
tion frequency but also to lethal vemrinlar arrhythrnias,
such as sustained ventricular techyeardia or 5bnllation . The
possibility of an ischemic substrate, which may be silent, has
been previously mentioned in relation to the observed rate of
ntrr-Q wave infarction (25). Other factors may include
ariation in catecholamines and autonomic tone (27,29),
on-going
ventricular remodeling and scar maturation (29)
and intermittent variation in degree of heart failure and wall
%tress (30) .
Condmioas. Initiation of therapy with the class I under .
rhythmic drags used in this study did not cause sustained but
nonfatal ventricular tachycardia . It did cause a three-fold
increase in arrhythmic death (1 .6% vs. 0.55'%: active drug vs .
placcbo) during the
fast few weeks of therapy. These theta
suggest that many but not all of the serious arrhythmic
events during drug titration were caused by the drugs and in
that sense were truly proarehythmic .
There sere no differences sassing the three CAST drugs
and placebo with respect to the incidence of increased
ventricular premature depolarization (3% to 5%) during this
same time period. Drug washout studies in a small number of
patients suggest that many of the increases in ventricular
premature depularizations were nut caused by the drugs .
These and other data suggest that . unlike serious arrhythmic
events, much of what has been termed "prcarrhythmia'
with respect to increased frequency of ventricular premature
depolneizatlons is in reality spontaneous variability of no-
rhythmia. Nevertheless, a marked increase in ventricular
premature depnlarirations during initiation of therapy with
one of the three CAST drugs predicts increased risk of
subsequent arrhythmic death, even though the drugs are not
continued .
The findings challenge some of the current thinking
concerning proaerhylbmia and suggest possible lines for
future investigation . First, the incidence of proarrhythmia
cannot be accurately described without placebo control .
Second . the definition of proarrhythntia that is based on
increased frequency of ventricular premature depolariza-
tion needs to be refined in specific subsets of patients .
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